pI: 9.5528 |
Length (AA): 946 |
MW (Da): 110240 |
Paralog Number:
1
Signal peptide: N | GPI Anchor: | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 60-80% percentile | Procyclic. | Siegel TN |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Mid 40-60% percentile | Bloodstream Form. | Siegel TN |
Siegel TN | Genome-wide analysis of mRNA abundance in two life-cycle stages of Trypanosoma brucei and identification of splicing and polyadenylation sites. |
Ortholog group members (OG5_129277)
Species | Accession | Gene Product |
---|---|---|
Dictyostelium discoideum | DDB_G0287291 | actin binding protein D |
Drosophila melanogaster | Dmel_CG6059 | CG6059 gene product from transcript CG6059-RA |
Drosophila melanogaster | Dmel_CG5882 | CG5882 gene product from transcript CG5882-RA |
Drosophila melanogaster | Dmel_CG40446 | Occludin-Related Y |
Echinococcus granulosus | EgrG_000954700 | coiled coil domain containing protein 147 |
Echinococcus multilocularis | EmuJ_000954700 | coiled coil domain containing protein 147 |
Giardia lamblia | GL50803_3409 | Coiled-coil protein |
Homo sapiens | ENSG00000120051 | cilia and flagella associated protein 58 |
Leishmania braziliensis | LbrM.35.5270 | hypothetical protein, conserved |
Leishmania braziliensis | LbrM.03.0310 | hypothetical protein, conserved |
Leishmania donovani | LdBPK_030300.1 | hypothetical protein, conserved |
Leishmania donovani | LdBPK_365250.1 | hypothetical protein, conserved |
Leishmania infantum | LinJ.36.5250 | hypothetical protein, conserved |
Leishmania infantum | LinJ.03.0300 | hypothetical protein, conserved |
Leishmania major | LmjF.36.5020 | hypothetical protein, conserved |
Leishmania major | LmjF.03.0320 | hypothetical protein, conserved |
Leishmania mexicana | LmxM.03.0320 | hypothetical protein, conserved |
Mus musculus | ENSMUSG00000046585 | cilia and flagella associated protein 58 |
Neospora caninum | NCLIV_023900 | hypothetical protein |
Plasmodium berghei | PBANKA_1125300 | conserved Plasmodium protein, unknown function |
Plasmodium falciparum | PF3D7_0626500 | conserved Plasmodium protein, unknown function |
Plasmodium knowlesi | PKNH_1123300 | conserved Plasmodium protein, unknown function |
Plasmodium vivax | PVX_114430 | hypothetical protein, conserved |
Plasmodium yoelii | PY07530 | hypothetical protein |
Schistosoma japonicum | Sjp_0111790 | IPR010978,tRNA-binding arm,domain-containing |
Schistosoma japonicum | Sjp_0045650 | Conserved hypothetical protein |
Schistosoma mansoni | Smp_156370 | hypothetical protein |
Schmidtea mediterranea | mk4.002732.02 | |
Trypanosoma brucei gambiense | Tbg972.10.4180 | hypothetical protein, conserved |
Trypanosoma brucei gambiense | Tbg972.11.12210 | hypothetical protein, conserved |
Trypanosoma brucei | Tb927.10.3310 | Component of motile flagella 76b |
Trypanosoma brucei | Tb927.11.10900 | Component of motile flagella 9 |
Trypanosoma congolense | TcIL3000.11.11580 | MENG |
Trypanosoma congolense | TcIL3000_10_2750 | hypothetical protein, conserved |
Trypanosoma cruzi | TcCLB.510941.20 | hypothetical protein, conserved |
Trypanosoma cruzi | TcCLB.508179.30 | hypothetical protein, conserved |
Trypanosoma cruzi | TcCLB.510423.70 | hypothetical protein, conserved |
Trypanosoma cruzi | TcCLB.510425.10 | hypothetical protein, conserved |
Trypanosoma cruzi | TcCLB.509825.20 | hypothetical protein, conserved |
Trichomonas vaginalis | TVAG_470210 | RAB6-interacting protein, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb11.01.2670 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (3 days) | alsford |
Tb11.01.2670 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (6 days) | alsford |
Tb11.01.2670 | Trypanosoma brucei | significant loss of fitness in procyclic forms | alsford |
Tb11.01.2670 | Trypanosoma brucei | significant loss of fitness in differentiation of procyclic to bloodstream forms | alsford |
Tb927.10.3310 this record | Trypanosoma brucei | significant loss of fitness in bloodstream forms (3 days) | alsford |
Tb927.10.3310 this record | Trypanosoma brucei | significant loss of fitness in bloodstream forms (6 days) | alsford |
Tb927.10.3310 this record | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb927.10.3310 this record | Trypanosoma brucei | significant loss of fitness in differentiation of procyclic to bloodstream forms | alsford |
PBANKA_1125300 | Plasmodium berghei | Dispensable | plasmo |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
Affected Entity | Phenotypic quality | Occurs in | Occurs at | Evidence | Observed in | Drugs/Inhibitors |
---|---|---|---|---|---|---|
cell proliferation (GO:0008283) | decreased (PATO:0000468) | bloodstream stage trypomastigotes (PLO:0027) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | decreased cell proliferation (significant loss of fitness) in bloodstream forms (stage 6 days). | References: | 21363968 | |
cell proliferation (GO:0008283) | normal (PATO:0000461) | procyclic (PLO:0034) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | normal cell proliferation (no significant loss or gain of fitness) in procyclic forms . | References: | 21363968 | |
cell proliferation (GO:0008283) | decreased (PATO:0000468) | procyclic (PLO:0034) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | decreased cell proliferation (significant loss of fitness) in differentiation of procyclic to bloodstream forms . | References: | 21363968 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Druggability index (range: 0 to 1): 0.1
1 literature reference was collected for this gene.